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ABSTRACT 
 
Aims: This was to determine efficacy and resistance profiles against commonly used commercial 
antibacterial agents in Uganda in the management of oral pathogens in HIV/AIDS patients. 
Study Design: This was an experimental study. 
Place and Duration of Study: Microbiology Laboratory, Mbarara University of Science and 
Technology, Mbarara, Uganda between September 2015 and February 2016.  
Methodology: Bacterial isolates were tested against commercial antibacterial agents in Uganda. 
Drug shops, pharmacies and hospitals were purposively and conveniently sampled. Drugs 
commonly used for the management of opportunistic infections amongst HIV/AIDS patients were 
purchased and used in the laboratory for susceptibility, minimum inhibitory concentration (MIC) and 
minimum bactericidal concentration (MBC) using standard protocols.  
Results: All the bacterial isolates showed mean total resistance above 60% against erythromycin 
[85 isolates (69.7%)] and cotrimoxazole [79 isolates, (64.8%)]; with injectable gentamicin [97 
isolates (79.5%)] and ceftriaxone [105 isolates (86.0%)] displaying high susceptibility; and 
ciprofloxacin [65 isolates (53.3%)] showing moderate susceptibility. This shows that national policy 
on effective regulation of these antibacterial agents needs to be revised to ensure that the situation 
is reversed. Gentamicin showed increased significant mean activity (P***< .005, ANOVA, multiple 
comparisons) in MIC and MBC when compared with the other antimicrobial agents.  
Conclusion: Gentamicin was highly efficacious in this study and resistance of these oral bacteria 
to common commercial antibacterial agents is a major public health burden especially among 
Uganda HIV/AIDS patients. Improving drug regulation activities will reduce antibacterial resistance 
and treatment failures. We recommend a survey on the reasons for efficacy of gentamicin against 
all the commercially available antimicrobials used in this study. 
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ABBREVIATIONS 
 
HIV  : Human Immunodeficiency Virus 
AIDS  : Acquired Immunodeficiency 
Syndrome 
MHA  : Mueller Hinton Agar 
API  : Analytical Profile Index  
MIC  : Minimum Inhibitory Concentration 
MBC  : Minimum Bactericidal Concentration  
MBCs  : Minimum Bactericidal 
Concentrations  
p (p value) : Probability value 
NDA  : National Drug Authority  
KIU-WC  : Kampala International University 
Western Campus  
NCCLS  : National Council for Clinical and 
Laboratory Standards 
CLSI  : Clinical and Laboratory Standards 
Institute 
ANOVA  : Analysis of Variance 
TASO  : The AIDS Support Organisation and  
UNCST  : Uganda National Council for Science 
and Technology. 
1. INTRODUCTION 
 
In a majority of developing countries including 
Uganda, the food and drug industries have been 
overly liberalized leading to passive regulation of 
pharmaceutical agents in a majority of 
communities [1]. This implies that individuals in 
communities can access medications without 
necessarily having a prescription from the 
hospital/health clinic. This is highly alarming in 
immune compromised individuals due to the risk 
of development of drug resistance [2]. In the 
management of opportunistic infections among 
HIV/AIDS patients, resistance to commonly used 
commercially available drugs would be a major 
blow on the promotion of health within this 
population [3,4]. Oral lesions in HIV/AIDS 
patients of South Western Uganda have been 
studied previously [5] and those due to bacterial 
pathogens have been shown to be the most 
prevalent in the region [6]. Moreover, recent 
findings from the region in the same population 
have shown that resistance to common 
Original Research Article 
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antibacterial agents is a real threat facing the 
medical profession and this patient population in 
the region [7], however, no information is 
available to date on the status of the efficacy of 
the available drugs in the market. This is 
important since great variations may exist 
between studies using antibacterial discs and the 
commercially available antibacterial agents 
needing effective regulation and monitoring by 
drug regulatory bodies. This implies that 
differences do exist between in vivo and in vitro 
studies, thus the need to get clear picture on the 
resistance burden in the region.  
 
In Uganda, regulation of the drug industry is 
under the National Drug Authority (NDA), which 
is responsible for controlling drug supply and 
consumption within the country, although this has 
been marred by a lot of challenges [8, 9]. After 
12 years of its incorporation, NDA still finds it 
challenging to enforce a majority of its major 
objectives, thus leading to increased exploitation 
of the vacuum by the general public in the use of 
drugs that are substandard [1]. In addition, 
regulating drug supply and distribution with a few 
personnel and large population of unregistered 
and improperly registered drug shops and 
pharmacies still continues to be the NDA’s major 
challenges in the execution of its duties. This 
shows that consumers may be exploited by 
private drug outlets due to this on-going uneasy 
battle by the NDA in combating uncontrolled 
supply, distribution, dispensing and 
administration of antibacterial agents in Uganda. 
Also, the limited number of drugs within the 
Ugandan market has been faced with a major 
limitation on pharmacovigilance as a result of 
limited national funding, limited trained human 
resource in the ministry, and poor coordination of 
national activities [10]. These weaknesses have 
subsequently created an open window for 
exploitation by the drug shops and 
pharmaceutical industries, which has been a 
major contributory factor to the development of 
drug resistance in Uganda [2,7]. 
 
Drug resistance to common antibacterial agents 
amongst HIV/AIDS patients of Uganda has been 
reported [6,7], however, information on the level 
of efficacy and resistance against commercially 
available antibacterials in the Ugandan market is 
still limited to date. This is because majority of 
the studies have been done in the laboratory with 
antibacterial discs and not antibacterials 
practically present in the market. Some of these 
commercial antibacterial agents when compared 
with the highly standardised antibacterial discs 
may be resisted by these oral pathogens of 
HIV/AIDS patients possibly due to availability of 
fake or substandard drugs in the market. This is 
conceivably subject to poor current good 
manufacturing practices, poor distribution and 
storage facilities. This seeming disinterest in 
studies on commercially available antibacterial 
agents leads to limited studies and information 
on the commonly available drugs currently in 
circulation in the market. This study would 
provide basic information which would help 
enforce policy in Uganda for effective drug 
regulation and promotion of health especially 
among HIV/AIDS patients. The objective of the 
study was to determine the efficacy of common 
commercial antibacterial agents and resistance 
patterns of oral bacterial isolates from HIV/AIDS 
patients in South Western Uganda against 
selected commercial antibacterial agents. 
 
2. MATERIALS AND METHODS 
 
2.1 Study Design 
 
The study design was experimental. Clinical oral 
bacterial isolates which had earlier been isolated 
[6] were provided by the Microbiology Laboratory 
cold store room of KIU-WC and analyzed. 
 
2.2 Sample Size and Sampling Technique 
 
A systematic-random sampling technique was 
used in selection of a sample of 100 bacterial 
isolates from 610 bacterial isolates identified in 
one of the previous studies [6]. Each bacterial 
isolate was selected in every 6th isolate (1:6). 
The first bacterial isolate was selected at 
random. Successively, a duplicate isolate of the 
standard bacteria was selected using gram 
negative or positive criteria for each set of the 
bacteria under study: Two isolates of ATCC 
25923 Staphylococcus aureus were selected to 
compare the activity of each of the pyogenic 
bacteria (that is, two isolates of reference ATCC 
25923 Staphylococcus aureus for comparison 
with Staphylococcus aureus, two isolates of 
reference ATCC 25923 Staphylococcus aureus 
for comparison with Staphylococcus 
saprophyticus, two isolates of reference ATCC 
25923 Staphylococcus aureus for comparison 
with Streptococcus mutans, two isolates of 
reference ATCC 25923 Staphylococcus aureus 
for comparison with Streptococcus pneumoniae, 
two isolates of reference ATCC 25923 
Staphylococcus aureus for comparison with non 
haemolytic streptococcus, and two isolates of 
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reference ATCC 25923 Staphylococcus aureus 
for comparison with Bacillus cereus making a 
total of 12 isolates of reference ATCC 25923 
Staphylococcus aureus; then two isolates of 
ATCC 25922 Escherichia coli were selected for 
comparison with each of the enterobacteriaceae 
which included Escherichia coli, Klebsiella 
pneumoniae, Salmonella pullorum and Proteus 
mirabilis making a total of eight isolates of 
reference ATCC 25922 Escherichia coli; and 
finally two isolates of ATCC 27853 
Pseudomonas aeruginosa were selected for 
comparison with Pseudomonas aeruginosa,   
thus making a grand total of 122 bacterial 
isolates used in the study (100 isolates of        
test bacteria and 22 isolates of reference 
bacteria).  
 
2.3 Selection of Commercial Antimicro-
bial Agents 
 
Commonly used commercial antibacterial agents 
were selected by purposive and convenience 
sampling in Bushenyi District specifically in 
Bushenyi – Ishaka Municipality and Mbarara 
District specifically in Mbarara Municipality of 
South Western Uganda. Sampling was 
conducted in pharmacies, drug shops and 
hospitals within these Districts. Antibacterial 
agents selected were known to be used for the 
management of opportunistic infections amongst 
HIV/AIDS patients. The antibacterials used with 
their strengths were gentamicin injectable (40 
mg/ml) and erythromycin suspension (25 mg/ml) 
purchased from a Drug Shop at Ishaka; 
cotrimoxazole suspension (8/40 mg/ml) 
purchased from a Pharmacy at Ishaka; 
ceftriaxone injectable (200 mg/ml) purchased 
from a Pharmacy at Mbarara; and ciprofloxacin 
injectable intravenous fluid (2mg/ml) purchased 
from a Hospital at Ishaka Town.  
 
2.4 Isolation and Identification of Bacteria 
 
MacConkey agar, Chocolate agar and Blood 
agar were used as the primary media to grow the 
122 samples to get fresh isolates. The identities 
of the previously identified isolates and standard 
bacteria were re-identified and ratified by growing 
the isolates on the suitable culture media 
(MacConkey agar, Chocolate agar and Blood 
agar) and applying microscopic gram stain, 
suitable oxidase and catalase biochemical tests 
[11–15], chrom-agar orientation and 
carbohydrate assimilation tests utilising the 
analytical profile index (API) testing kits 
(Biomerieux® SA France, INS005517) employing 
apiweb TM identification software. 
2.5 Susceptibility Testing 
 
A 1.5 McFarland standard was used to prepare a 
bacterial suspension from an overnight culture 
with an equivalent turbidity standard measured 
with a densitometer for clarity. The suspension 
was made uniform with a homogenizer and 
instantly used. The sensitivity, MIC and MBC of 
all purified isolates were measured in 
accordance with methods described by 
Cheesbrough [11]. Antibacterial activities of the 
antibacterial agents against the purified bacterial 
isolates were determined with NCCLS (now 
called CLSI) [16] modified Kirby-Buaer tube 
dilution and agar well diffusion methods for 
bacterial sensitivity and resistance patterns, MIC 
and MBC [11]. The standard organisms of 
American Type Culture Collection (ATCC 25923 
Staphylococcus aureus for pyogenic bacteria, 
ATCC 25922 Escherichia coli for 
enterobacteriaceae and ATCC 27853 
Pseudomonas aeruginosa) for Pseudomonas 
aeruginosa were used as the controls for the 
tests.  
 
2.6 Preparation of Broth for MIC 
 
The suspension of 18-24 hour freshly sub-
cultured bacterial strains was inoculated on 
freshly prepared Mueller Hinton agar (MHA) on 
which holes were made with a sterile cork borer. 
The sensitivity and resistance patterns, MIC and 
MBC were determined following the standard 
conventional method [11]. The specific 
concentrations of the antibacterial agents 
prepared by their respective manufacturers in 1 
mL of water for injection were each used as 
stock solutions in sterile plain tubes. They 
included gentamicin (40 mg/ml), ciprofloxacin 
injectable intravenous fluid (2 mg/ml), 
erythromycin suspension (25 mg/ml), 
cotrimoxazole suspension (8/40 mg/ml) and 
ceftriaxone injectable (200 mg/ml)). A 200 µL of 
the stock solution of the antibacterial agent was 
pipetted into each of the holes made on the 
media, incubated for 18-24 hours and then  
zones of inhibition were measured with a 
transparent ruler and recorded for analysis of 
sensitivity and resistance patterns. Afterwards, 
serial dilutions ranging from 0.5 to 0.004 strength 
of each of the stock solutions were made using 
1mL of distilled water in each case [17,18]. Then, 
200 µL of each dilution was pipetted with a 
micropipette into respective holes made on the 
agar plate for agar well diffusion starting with    
the lowest dilution. The plates and the          
tubes were incubated at 37°C for 18-24 hours, 
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checked for growth and zone of inhibition in the 
petri dishes.  
 
2.7 MIC and MBC Determination 
 
MIC was determined by recording the smallest 
concentration of the drug that inhibited growth of 
microorganisms. But MBC could not directly be 
determined from the tubes because of high 
turbidity in the tubes. Hence, samples were taken 
with sterile swab sticks from cleared zones of 
inhibition taking cognizance of each specific 
dilution on the petri dishes and then smeared 
onto a fresh Mueller Hinton agar medium and 
incubated for 18-24 hours and then results were 
checked for MBC as the smallest concentration 
of the drug that killed the organisms i.e. the plate 
in which the smallest concentration of the drug 
disallowed the re-growth of the organisms [11].  
 
2.8 Data Analysis 
 
The duplicates of the data were entered in MS 
Excel and analysis was conducted using Graph 
Pad Prism Version 6. Information was expressed 
as mean ±SEM. One-way ANOVA was 
conducted and significance was considered 
when P < .05. Multiple comparisons were 
conducted and a Tukey’s test was used to 
determine sources of variation between groups 
at 95% significance. 
 
3. RESULTS 
 
3.1 Susceptibility and Resistance 
Patterns of Oral Bacteria 
 
Major resistance was recorded with erythromycin 
and cotrimoxazole at [39 (88.6%)] and [37 
(84.1%)] respectively for Staphylococcus aureus 
isolates; at [1 (100%)] for Staphylococcus 
saprophyticus and [9 (100%)] for Klebsiella 
pneumoniae; at [8 (88.9%)] and [7 (77.8%)] 
respectively for E. coli; at [7 (77.8%)] and [6 
(66.7%)] respectively for Streptococcus mutans; 
at [15 (71.4%)] and [14 (66.7%)] respectively for 
Streptococcus pneumoniae; and at [2 (100%)] 
and [1 (50%)] respectively for Proteus mirabilis. 
Salmonella pullorum was [1 (100%)] resistant to 
erythromycin, cotrimoxazole and ceftriaxone. 
Pseudomonas aeruginosa demonstrated 
resistance to all the antibacterial agents except 
ceftriaxone whereas Bacillus cereus was 
resistant to all the antibacterial agents except 
gentamicin and ceftriaxone. However, 
antibacterial activity was observed with 
gentamicin and ceftriaxone at [33 (75%)] for 
Staphylococcus aureus isolates; at [6 (66.7%)] 
and [8 (88.9%)] respectively for Klebsiella 
pneumoniae isolates; at [8 (88.9%)] for 
Streptococcus mutans isolates; at [14 (66.7%)] 
and [21 (100%)] respectively for Streptococcus 
pneumoniae isolates and at [1 (100%)] for 
Staphylococcus saprophyticus, at [2 (100%)] for 
Proteus mirabilis and at [1 (100%)] for Bacillus 
cereus isolates. Gentamicin and ciprofloxacin 
had [1 (100%)] antibacterial activity against 
Salmonella pullorum isolates. Ciprofloxacin also 
had [1 (100%)] activity against only one isolate of 
Staphylococcus saprophyticus. Ceftriaxone 
recorded [21 (100%)] activity against isolates of 
Streptococcus pneumoniae and [2 (100%)] 
against isolates of Pseudomonas aeruginosa. 
Gentamicin, ciprofloxacin and ceftriaxone scored 
antibacterial activity against E. coli isolates at [8 
(88.9%)], [6 (66.7%)] and [6 (66.7%)] 
respectively. Non haemolytic streptococcus [1] 
and all the reference bacteria such as 
Staphylococcus aureus ATCC 25923 [12], 
Escherichia coli ATCC 25922 [8] and 
Pseudomonas aeruginosa ATCC 27853 [2] 
isolates yielded 100% to all the antibacterial 
agents used. Gentamicin, ciprofloxacin and 
ceftriaxone displayed respective mean total 
sensitivities of [97 (78.5%)], [65 (53.3%)] and 
[105 (86%)]. Erythromycin and cotrimoxazole 
showed mean total resistance of [85 (69.7%)] 
and [79 (64.8%)] respectively as shown in    
Table 1. 
 
3.2 Minimum Inhibitory Concentration 
(MIC)  
 
Major isolates were gram positive bacteria and 
few were gram negative bacteria. Among these, 
their efficacy and resistance against the common 
antibacterial agents in the market as compared 
to their controls and other groups were noted. 
Statistical significant differences in MIC activity 
were noticed in only gentamicin activity against 
gram positive Staphylococcus aureus, 
Streptococcus mutans and Streptococcus 
pneumoniae and gram negative Escherichia coli 
and Klebsiella pneumoniae isolates (One-way 
ANOVA, P < .05) as shown in Table 2. From 
table 1, ceftriaxone demonstrated efficacy 
against most of the bacteria except Salmonella 
pullorum. However, from table 2, the MIC data 
showed non significant differences in activities of 
ceftriaxone, ciprofloxacin, erythromycin and 
cotrimoxazole. Tukey’s multiple comparison tests 
further revealed significant differences in MIC 
activities on Staphylococcus aureus, 
Streptococcus mutans, Streptococcus 
pneumoniae, Escherichia coli and Klebsiella 
pneumoniae when gentamicin bactericidal 
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activity was compared with ciprofloxacin, 
erythromycin, cotrimoxazole and ceftriaxone 
(Table 4).  
 
3.3 Minimum Bactericidal Concentration 
(MBC) 
 
Minimum bactericidal concentration (MBC) was 
reached and was statistically significant in 
gentamicin (ANOVA, P< .05) and this was in 
response to Staphylococcus aureus [P**** = 
.0001], Streptococcus pneumoniae [P**** = 
.0001], Escherichia coli [P*** = .0006] and 
Klebsiella pneumoniae [P****  = .0001] (Table 3). 
Equally, Tukey’s multiple comparisons showed 
gentamicin to be the only commercial 
antibacterial agent with statistical significant 
differences in bactericidal activities of 
Staphylococcus aureus, Streptococcus mutans, 
Streptococcus pneumoniae, Escherichia coli and 
Klebsiella pneumoniae when gentamicin 
bactericidal activity was compared with 
ciprofloxacin, erythromycin, cotrimoxazole and 
ceftriaxone (Table 5). Erythromycin and 
cotrimoxazole respectively did not have any 
bactericidal activity against Klebsiella 
pneumoniae, Pseudomonas aeruginosa, 
Salmonella pullorum, Staphylococcus 
saprophyticus, Bacillus cereus and Proteus 
mirabilis. Ciprofloxacin and ceftriaxone exhibited 
no bactericidal activity against Bacillus cereus 
and Staphylococcus saprophyticus respectively. 
Besides the above stated bactericidal activities of 
gentamicin, the other commercially available 
antibacterial agents did not record any 
statistically significant bactericidal activity with 
analysis of variance and Tukey’s multiple 
comparisons of the means as shown in tables 3 
and 5. 
 
4. DISCUSSION 
 
Resistance (> 60%) against commonly used  and 
commercially available antibacterial agents was 
demonstrated in this study with gentamicin 
proving to be the most commonly used effective 
antibacterial agent in the Ugandan market.  
There is a worldwide pointer to frequent 
unbefitting use of antibacterials [19]; Perhaps 
contributing to antibacterial resistance, which is 
reaching worrying heights in Southern and 
Eastern Europe [20]. Ignoring the issue of 
antibacterial resistance leads to unfavourable 
medical consequences, including considerable 
ecological and economic implications [21-24]. 
This study has shown that liberalization of drugs 
use, drugs manufacturing, distribution and 
warehousing in developing countries results to 
non observance of existing rules and regulations 
in daily routine transactions and activities. This 
may culminate in poor current good 
manufacturing practices leading to production of 
fake or substandard drugs which are not 
adequately and regularly checked by      
regulatory authorities; Thus creating impunity 
and disregard for standards in the drug     
industry, drug supply and distribution chains. 
Hence, this  is a major threat to the    
sustainability of the drug industry and above all, 
a public health concern as a result of         
passive regulations and their poor 
implementation in the drug industry and 
distribution sector in Uganda [1]. This situation 
can be further compounded by several        
factors such as frequent availability and 
uncontrolled access to antibacterial agents by 
the populace without prescription in private 
pharmacies and drug shops, lack of updated 
national guidelines for antimicrobial use for 
primary care physicians, self storage of 
antibacterials in home pharmacies without 
permission, improper guides and instructions, 
improper storage conditions in pharmacies and 
drug shops, unstreamlined health system, 
insatiable self health seeking behaviours, undue 
methods of supply and dispensing of 
antibacterials, different attitudes and levels of 
knowledge about antibacterial agents among 
various patients and their cultures and beliefs 
[25]. Sometimes, the reason for inefficacy may 
be improper storage as shown in a study in 
Serbia where antibiotics were found to be     
most commonly stored in the refrigerator without 
such indication, in the kitchen or bathroom   
where they were either exposed to unusual 
temperatures, heat and moisture thereby   
causing their accelerated spoilage. Sometimes, 
these drugs might have expired and been 
relabelled by unscrupulous dealers. Sometimes, 
they might have been damaged in transit or       
by exposure to excessive light in transit or 
storage without prior knowledge preceding use   
in treatment. This, hence, may result to failure    
in treatment and this failure can be    
misconstrued and misinterpreted as resistance 
[25]. These issues plausibly lead to increased 
spending on drugs that are not working in 
immune-compromised patients. The ministry 
would also have to spend more on worthless 
drugs in the HIV/AIDS community,                 
since more costly drugs would have to be 
procured [2,3].  
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Table 1. Susceptibility and resistance patterns against commercial antimicrobial agents in study area 
 
Bacteria No. of 
isolates (N) 
S/R/I Antibacterial agent 
Genta  (40 mg/ml) Ciprof 
(2 mg/ml) 
Eryth 
 (25 mg/ml) 
Cotri 
(8/40 mg/ml) 
Ceftri 
(200 mg/ml) 
Staphylococcus aureus 44 S 33a (75.0)b 18 a (40.9) b 1 a (2.3) b 5 a (11.4) b 33 a (75.0) b 
R 11 a (25.0) b 20 a (45.5) b 39 a (88.6) b 37 a (84.1) b 11 a (25.0) b 
I 0 a (0.0) b 6 a (13.6) b 4 a (9.1) b 2 a (4.5) b 0 a (0.0) b 
SA ATCC 25293 12 S 12 a (100.0) b 12 a (100.0) b 12 a (100.0) b 12 a (100.0) b 12 a (100.0) b 
Staphylococcus saprophyticus 1 S 1 a (100.0) b 1 a (100.0) b 0 a (0.0) b 0 a (0.0) b 1 a (100.0) b 
R 0 a (0.0) b 0 a (0.0) b 1 a (100.0) b 1 a (100.0) b 0 a (0.0) b 
I 0 a (0.0) b 0 a (0.0) b 0 a (0) b 0 a (0.0) b 0 a (0.0) b 
Escherichia coli 9 S 8 a (88.9) b 6 a (66.7) b 1 a (11.1) b 0 a (0.0) b 6 a (66.7) b 
R 0 a (0.0) b 2 a (22.2) b 8 a (88.9) b 7 a (77.8) b 0 a (0.0) b 
I 1 a (11.1) b 1 a (11.1) b 0 a (0.0) b 2 a (22.2) b 3 a (33.3) b 
Escherichia coli ATCC 25922 8 S 8 a (100.0) b 8 a (100.0) b 8 a (100.0) b 8 a (100.0) b 8 a (100.0) b 
Salmonella pullorum 1 S a1 (100.0) b 1 a (100.0) b 0 a (0.0) b 0 a (0.0) b 0 a (0.0) b 
R 0 a (0) b 0 a (0) b 1 a (100.0) b 1 a (100.0) b 1 a (100.0) b 
I 0 a (0) b 0 a (0) b 0 a (0.0) b 0 a (0.0) b 0 a (0.0) b 
Klebsiella pneumoniae 9 S 6 a (66.7) b 3 a (33.3) b 0 a (0.0) b 0 a (0.0) b 8 a (88.9) b 
R 3 a (33.3) b 5 a (55.6) b 9 a (100.0) b 9 a (100.0) b 0 a (0.0) b 
I 0 a (0.0) b 1 a (11.1) b 0 a (0.0) b 0 a (0.0) b 1 a (11.1) b 
Streptococcus mutans 9 S 8 a (88.9) b 4 a (44.4) b 2 (22.2) b 3 (33.3) b 8 (88.9) b 
R 1 a (11.1) b 3 a (33.3) b 7 a (77.8) b 6 a (66.7) b 1 a  (11.1) b 
I 0 a (0.0) b 2 a  (22.2) b 0 a (0.0) b 0 a (0.0) b 0 a (0.0) b 
Streptococcus pneumoniae 21  S 14 a (66.7) b 9 a (42.9) b 3 a (14.3) b 4 a (19.0) b 21 a (100.0) b 
R 3 a (14.3) b 5 a (23.8) b 15 a (71.4) b 14 a (66.7) b 0 a (0.0) b 
I 4 a (19.0) b 7 a  (33.3) b 3 a (14.3) b 3 a (14.3) b 0 a (0.0) b 
Non haemolytic streptococcus 1 S 1 a (100.0) b 1 a (100.0) b 1 a (100.0) b 1 a (100.0) b 1 a (100.0) b 
R 0 a (0) b 0 a (0) b 0 a (0.0) b 0 a (0.0) b 0 a (0.0) b 
I 0 a (0) b 0 a (0) b 0 a (0.0) b 0 a (0.0) b 0 a (0.0) b 
Proteus mirabilis 2 S 2 a (100.0) b 1 a (50.0) b 0 a (0.0) b 1 a (50.0) b 2 a (100.0) b 
R 0 a (0.0) b 0 a (0.0) b 2 a (100.0) b 1 a (50.0) b 0 a (0) b 
I 0 a (0.0) b 1 a (50.0) b 0 a (0.0) b 0 a (0.0) b 0 a (0) b 
Pseudomonas aeruginosa 2 S 0 a (0.0) b 0 a (0) b 0 a (0.0) b 0 a (0.0) b 2 a (100.0) b 
R 2 a (100.0) b 2 a (100.0) b 2 a (100.0) b 2 a (100.0) b 0 a (0.0) b 
I 0 a (0.0) b 0 a (0.0) b 0 a (0.0) b 0 a (0.0) b 0 a (0.0) b 
Pseudomonas ATCC 27853 2 S 2 a (100.0) b 2 a (100.0) b 2 a (100.0) b 2 a (100.0) b 2 a (100.0) b 
Bacillus cereus 1 S 1 a (100.0) b 0 a (0.0) b 0 a (0.0) b 0 a (0.0) b 1 a (100.0) b 
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Bacteria No. of 
isolates (N) 
S/R/I Antibacterial agent 
Genta  (40 mg/ml) Ciprof 
(2 mg/ml) 
Eryth 
 (25 mg/ml) 
Cotri 
(8/40 mg/ml) 
Ceftri 
(200 mg/ml) 
R 0 a (0.0) b 1 a (1.00.0) b 1 a (100.0) b 1 a (100.0) b 0 a (0.0) b 
I 0 a (0.0) b 0 a (0.0) b 0 a (0.0) b 0 a (0.0) b 0 a (0.0) b 
Total 
 
 
122 S 
R 
I 
97 a (79.5) b 
20 a (16.4) b 
5 a   (4.1) b 
65 a (53.3) b 
38 a (31.1) b 
19 a (15.6) b 
30 a (24.6) b 
85 a (69.7) b 
7 a   (5.7) b 
36 a (29.5) b 
79 a (64.8) b 
7 a   (5.7) b 
105 a (86.0) b 
13 a  (10.7) b 
4 a    (3.3) b 
KEY: Genta = Gentamicin; Ciprof = Ciprofloxacin; Eryth = Erythromycin; Ceftri = Ceftriaxone; S = Sensitive; R = Resistant; I = intermediate sensitive ; E. coli = Escherichia coli, SA = Staphylococcus 
aureus; and ATCC = American Type Culture Collection; a = Number of bacteria; b = Percentage of bacteria. 
 
Table 2. Mean MIC of commercial antibacterial agents against oral bacteria in the study area 
 
Bacteria isolated N Genta Ciprof Eryth Cotri Ceftri Water 
Mean MIC ± SEM (µg/ml) 
Staphylococcus aureus 44 14.79±2.7**** 2.73±1.02 0.41±0.14 3.11±1.50 0.16±0.02 0.00±0.00 
Escherichia coli 9 2.69±0.55**** 0.13±0.03 0.48±0.30 0.11±0.06 0.22±0.05 0.00±0.00 
Streptococcus mutans 9 3.16±0.56*** 1.14±0.48 0.58±0.36 0.89±0.59 0.12±0.03 0.00±0.00 
Klebsiella pneumoniae 9 2.27±0.68*** 0.51±0.28 0.00±0.00 0.00±0.00 0.10±0.03 0.00±0.00 
Streptococcus pneumoniae 21 3.64±0.25**** 0.74±0.20 0.71±0.25 1.12±0.40 0.20±0.03 0.00±0.00 
Pseudomonas aeruginosa 2 0.40±0.00 0.10±0.00 0.00±0.00 0.00±0.00 1.00±0.00 0.00±0.00 
NH streptococcus. 1 4.00±0.00 0.20±0.00 2.50±0.00 0.40±0.00 0.06±0.00 0.00±0.00 
Proteus mirabilis 
Staphylococcus saprophyticus 
Salmonella pullorum 
2 
1 
1 
22.0±18.0 
0.40 ± 0.00 
0.40 ± 0.00 
0.11±0.09 
  0.20 ±0.00 
  0.20 ±0.00 
0.00±0.00 
0.00±0.00 
0.00±0.00 
20.0±20.0 
0.00±0.00 
0.00±0.00 
0.16±0.09 
0.00±0.00 
0.13±0.00 
0.00±0.00 
0.00±0.00 
0.00±0.00 
Bacillus cereus 1 4.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 1.00±0.00 0.00±0.00 
Pseudomonas aeruginosa ATCC 27853 2 0.40±0.00 0.00±0.00 0.03±0.00 0.40±0.00 0.06±0.00 0.00±0.00 
Escherichia coli ATCC 25922 8 0.04±0.00 0.00±0.00 0.25±0.00 0.40±0.00 0.06±0.00 0.00±0.00 
Staphylococcus aureus ATCC 25923 12 0.40±0.00 0.02±0.00 0.25±0.00 0.40±0.00 0.00±0.00 0.00±0.00 
KEY: Genta = Gentamicin; Ciprof = Ciprofloxacin; Eryth = Erythromycin; Cotri = Cotrimoxazole; Ceftri = Ceftriaxone; N = number of isolates; ATCC = American Type Culture Collection and Water = 
Distilled water; (ANOVA, P < .001); Multiple comparisons (P*** < .05) when compared with all groups. 
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Table 3. Mean MBC of commercial antimicrobial agents against oral bacteria in study area 
 
Bacteria isolated 
  
N 
  
Genta Cipro Eryth Cotri Ceftri          Water 
MBC                                         Mean ± SEM  
Staphylococcus aureus 44 18.42±2.79*** 2.12±0.79 1.26±0.73 1.08±0.84 0.31±0.04 0.00±0.00 
Escherichia coli 9 24.0±6.33*** 3.58±2.07 0.28±0.28 4.44±4.44 4.89±2.86 0.00±0.00 
Streptococcus pneumoniae 21 22.67±4.07*** 7.44±1.99 8.33±2.64 4.00±2.62 0.60±0.14 0.00±0.00 
Klebsiella. Pneumoniae 9 18.67±6.77*** 0.47±0.29 0.00±0.00 0. 00±0.00 0.36±0.00 0.00±0.00 
Pseudomonas aeruginosa 2 4.00±0.00 1.00±1.00 0.00±0.00 0.00±0.00 2.00±0.00 0.00±0.00 
Salmonella pullorum 1 4.00±0.00 2.00±0.00 0.00±0.00 0.00±0.00 0.40±0.00 0.00±0.00 
Staphylococcus saprophyticus 1 4.00±0.00 2.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 
Non Haemolytic streptococcus 1 40.00±0.00 2.00±0.00 25.00±0.00 40.00±0.00 0.50±0.00 0.00±0.00 
Proteus mirabilis 
Streptococcus mutans 
2 
9    
40.00±0.00 
19.58 ± 19.44 
1.10 ± 1.27 
5.16 ± 8.52 
0.0 ± 0.00 
3.28 ± 8.21 
 0.00±0.00   
8.89±17.64 
0.31±0.27 
0.32±0.22 
0.00 ±0.00 
0.00±0.00 
Staphylococcus aureus ATCC 25923 12 4.0±0.00 0.4±0.00 2.5±0.00 4.0±0.00 0.04±0.00 0.00±0.00 
Escherichia coli ATCC 25922 8 0.4±0.00 0.02±0.00 4.0±0.00 4.0±0.00 0.13±0.00 0.00±0.00 
Pseudomonas aeruginosa ATCC 27853 2 4.0±0.00 2.0±0.00 0.0±0.00 0.0±0.00 2.0±0.00 0.00±0.00 
Bacillus cereus 1 40.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 2.00±0.00 0.00±0.00 
KEY: Genta = Gentamicin; Ciprof = Ciprofloxacin; Eryth; Erythromycin; Cotri = Cotrimoxazole; Ceftri = Ceftriaxone; N = number of isolates; N = number of isolates, ATCC = American Type Culture 
Collection and Water = Distilled water; ANOVA (P< .05); Multiple comparisons (P***< .05 when compared with all groups. 
 
Table 4. MIC confident intervals and P values from Tukey’s multiple comparisons test (α<0.05) 
 
Bacterium under 
consideration 
Antibacterials under comparison 
Gentamicin vs. Ciprofloxacin Gentamicin vs. Erythromycin Gentamicin vs. Cotrimoxazole Gentamicin vs. 
Ceftriaxone 
P value 
 
95% confidence 
interval 
P value 
 
95% confidence 
interval 
P value 
 
95% confidence 
interval 
P value 
 
95% confidence 
interval 
Staphylococcus aureus P**** = 0.0001 1.433 -3.690 P**** = 0.0001 1.085 - 3.342 P**** = 0.0001 1.453 - 3.710 P**** = 0.0001 1.347 - 3.604 
Streptococcus mutans P* = .0237 0.1934 –3.842 P** = .0021 0.7534 - 4.402 P** = .0084 0.4423 - 4.091 P*** = .0002 1.213 - 4.862 
Streptococcus 
pneumoniae 
P**** = .0001 1.895 - 3.911 P**** = .0001 1.916 - 3.932 P**** = .0001 1.468 - 3.484 P**** = .0001 2.434 - 4.450 
Escherichia coli P**** = .0001 1.535 - 4.150 P**** = .0001 1.865 - 4.480 P**** = .0001 1.448 - 4.063 P**** = .0001 1.643 - 4.257 
Klebsiella pneumoniae P** = .0051 0.1934 - 3.842 P*** = .0002 0.9251 - 3.608 P*** = .0002 0.9251 - 3.608 P*** = .0002 1.213 - 4.862 
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Table 5. MBC confident intervals and P values from Tukey’s multiple comparisons test (α<0.05) 
 
Bacterium under 
consideration 
Antibacterials under comparison 
Gentamicin vs. Ciprofloxacin Gentamicin vs. Erythromycin Gentamicin vs. Cotrimoxazole Gentamicin vs. 
Ceftriaxone 
P value 95% confidence 
interval 
P value 95% Confidence 
interval 
P value 95% Confidence 
interval 
P value 95% Confidence 
interval 
Staphylococcus 
aureus 
P**** = .0001 10.90 - 21.69 P**** = .0001 11.77 - 22.56 P**** = .0001 11.94 - 22.73 P**** = .0001 12.71 - 23.50 
Streptococcus 
mutans 
P* = .0231 1.901 - 36.57 - - - - - - 
Streptococcus 
pneumoniae 
P*** = .0008 4.930 - 25.53 P** = .0018 4.034 - 24.63 P**** = .0001 8.368 - 28.97 P**** = .0001 11.77 - 32.37 
Escherichia coli P** = .0042 5.065 - 35.78 P*** =  .0007 8.365 - 39.08 P** = .0066 4.198 - 34.91 P** = .0083 3.754 - 34.47 
Klebsiella 
Pneumoniae 
P** = .0011 5.966 - 30.43 P*** = .0008 6.433 - 30.90 P*** = .0008 6.433 - 30.90 P** = .0010 6.072 - 30.54 
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This study has been able to provide more insight 
into the challenges faced by the national drug 
regulatory agencies such as NDA in this regard. 
This study also gives insight into the 
complications and impediments associated with 
such regulatory ineptitude. The use of 
commercially available antimicrobial agents in 
the market would probably influence policy 
change for the enactment of up- to-date drugs’ 
laws in Uganda. This study has also provided 
further value and understanding of antibacterial 
resistance in the context of associated 
contributory factors in HIV/AIDS patients in 
Uganda shedding more light on the reason for 
the previous study [7]. This has further validated 
the findings in the previous study [7], that 
resistance of opportunistic infective agents 
against publicly availed drugs in Uganda is a 
major public health threat [6,26]. NDA has faced 
a couple of challenges in enforcing its major 
objectives nationwide as a result of conflicting 
governmental policies in the drug industry, and 
inimically unexplained and uncomfortable 
prolonged delay in the passage of necessary 
drug control bills into laws and enabling 
legislations by the Parliament of Uganda [1]. The 
high rate of unlicensed drug shops has 
continuously made this difficult, amidst a 
misplaced priority and limited budget from the 
central government to fund its monitoring 
activities [10]. This implies that majority of drugs 
are bound to be abused by the general public 
since access to drugs does not necessarily 
require a prescription from the doctor [27,28].  
 
These operational conditions in Uganda, have 
led to the exploitation of the general public who 
would easily misunderstand dosage instructions 
or simply not adhere to treatment regimens 
[29,30]. Information on the ability of HIV/AIDS 
patients to effectively avoid misunderstanding 
instructions in the region is limited till date, thus 
showing the NDA still has a lot of work to 
conduct within Uganda. Once more information is 
obtained, strategies on how best to help 
communities would be exploited and these would 
help to arrest or reduce the escalating problems 
being expounded in these studies [6,7]. This is 
important since a majority of oral isolates 
identified in these studies are gram positive and 
should be easy to control through an improved 
national policy plan by the responsible 
authorities. 
 
Gentamicin showed significant MIC and MBC 
activities probably due to its low usage by 
patients and low sales by the drug shops and 
pharmacies in Uganda. This can be attributable 
to the injectable nature of gentamicin associated 
with pain and phlebitis at the site of injection and 
discomforting adverse effect of ototoxicity and 
fear of renal toxicity. Gentamicin is a major broad 
spectrum antibacterial agent in the therapeutic 
class of aminoglycosides and it is rarely 
recommended for wider public usage for 
management and control of infections especially 
amongst HIV/AIDS patients because it is orally 
non-absorbable and can only be injected which 
patients dislike. This shows that the limited use 
was  not because of strict control by regulatory 
authorities hence demanding the role of NDA in 
Uganda to be strengthened to ensure that 
challenges met are removed for increased 
consumer protection, through improved drug 
regulation [1]. Improved pharmacovigilance 
would help narrow the gap being created in the 
efficacy of available commercial antibacterial 
agents in Uganda against the threat being posed 
by the high trend of resistance especially in 
immuno-compromised patients. 
 
5. CONCLUSION AND RECOMMENDA-
TIONS 
 
Bacterial resistance against commercially 
available antibacterials in the Ugandan market 
has been demonstrated in this study. This would 
be due to challenges faced by the regulatory 
authorities within the nation. Gentamicin was the 
most efficacious agent identified in this study with 
a statistical difference and this might be due to its 
low usage among the general public, possibly 
owing to its mode of administration as an 
injectable. Improvement in drug regulatory 
policies would probably lead to reduced 
development of resistant microbial strains and 
treatment failures in Uganda. We strongly 
recommend a survey on the reason for high 
efficacy of gentamicin on the oral bacteria of 
HIV/AIDS patients in South Western Uganda to 
be conducted. 
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